Neoantigen Based Therapeutic Cancer Vaccines: Rationale, Practice and Perspectives in Endometrial Cancer (EACR 2023)
FSPs were compared to the the previously validated pool of nAgs included in the Nous-209 vaccine at present under evaluation in metastatic MSI solid tumours by Nouscom® (NCT04041310).Results and DiscussionsOf the 35 patients with dMMR, 4 showed an absence of protein expression for hMLH1, 20 for hMLH1/PMS2, 1 for hMSH2/hMSH6, 2 for hMSH6, 7 for PMS2, and 1 for hMSH2 alone...Moreover, samples of our series that showed loss of expression of hMLH1 or hMLH1/PMS2 showed a higher number of FSPs (21 FSPs). Several potential indels leading to FSPs have been reported as well as the identification of a molecular-defect-based behaviour in nAgs enrichment and demonstration of the feasibility of the proteogenomic approach in nAgs prediction and targeting for immunotherapy.ConclusionnAgs have a special value combined as biomarker-driven therapy to novel drug combinations resulting in a novel therapeutic approach that could remodel the management of malignant gynecological cancers.